In addition, inhibition of USP47 has been suggested as a novel targeted therapy to overcome resistance to tyrosine kinase inhibitors in chronic myelogenous leukemia (CML)10 and hematologic malignancies expressing mutant EZH211. Here, USP47 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.